Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
2017 · The Lancet · 197 citations
https://doi.org/10.1016/s0140-6736(17)30930-3
D
Dino Tarabar
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
99
Papers
1.4K
Citations
16
h-index
22
i10-index
Dino Tarabar is an academic researcher from University Hospital Center Dr Dragiša Mišović. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Colorectal Cancer Treatments and Studies. The author has an h-index of 16, co-authored 85 publications.
Papers by this author
worksPhase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
2017 · Gut · 107 citations
https://doi.org/10.1136/gutjnl-2016-313457
Risankizumab for Ulcerative Colitis
2024 · JAMA · 98 citations
https://doi.org/10.1001/jama.2024.12414
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2023 · The Lancet. Gastroenterology & hepatology · 61 citations
https://doi.org/10.1016/s2468-1253(23)00318-7
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
2021 · Journal of Crohn s and Colitis · 34 citations
https://doi.org/10.1093/ecco-jcc/jjab023
Supplementary Material for: Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus
2019 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.7679885
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat